Topics

Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market

09:13 EDT 30 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has entered into definitive agree...

Other Sources for this Article

Investor Contacts
Timothy McCarthy
LifeSci Advisors, LLC
Tel: 212-915-2564
tim@lifesciadvisors.com

NEXT ARTICLE

More From BioPortfolio on "Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...